<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> and a defective insulin activation of the enzyme <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase in skeletal muscle during euglycaemia may have important pathophysiological implications in Type 2 (non-insulin-dependent) <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">Hyperglycaemia</z:e> may serve to compensate for these defects in Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by increasing <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal through a mass action effect </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, rates of whole-body <z:chebi fb="105" ids="17234">glucose</z:chebi> oxidation and <z:chebi fb="105" ids="17234">glucose</z:chebi> storage were measured during fasting <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and isoglycaemic insulin infusion (40 mU.m-2.min-1, 3 h) in 12 patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Eleven control subjects were studied during euglycaemia </plain></SENT>
<SENT sid="4" pm="."><plain>Biopsies were taken from the vastus lateralis muscle </plain></SENT>
<SENT sid="5" pm="."><plain>Fasting and insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> oxidation, <z:chebi fb="105" ids="17234">glucose</z:chebi> storage and muscle <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase activation were <z:hpo ids='HP_0000001'>all</z:hpo> fully compensated (normalized) during <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in the diabetic patients </plain></SENT>
<SENT sid="6" pm="."><plain>The insulin-stimulated increase in muscle <z:chebi fb="15" ids="28087">glycogen</z:chebi> content was the same in the diabetic patients and in the control subjects </plain></SENT>
<SENT sid="7" pm="."><plain>Besides <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, the diabetic patients had elevated muscle free <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="105" ids="17234">glucose</z:chebi> 6-phosphate concentrations </plain></SENT>
<SENT sid="8" pm="."><plain>A positive correlation was demonstrated between intracellular free <z:chebi fb="105" ids="17234">glucose</z:chebi> concentration and muscle <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase fractional velocity insulin activation (0.1 mmol/l <z:chebi fb="105" ids="17234">glucose</z:chebi> 6-phosphate: r = 0.65, p less than 0.02 and 0.0 mmol/l <z:chebi fb="105" ids="17234">glucose</z:chebi> 6-phosphate: r = 0.91, p less than 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, this study indicates an important role for <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and elevated muscle free <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="105" ids="17234">glucose</z:chebi> 6-phosphate concentrations in compensating (normalizing) intracellular <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism and skeletal muscle <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase activation in Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>